← All trials
NCT04819412
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Mar 20, 2015
- Primary completion
- Oct 30, 2015
- Completion date
- Dec 30, 2016
- First posted
- Mar 29, 2021
- Last posted
- Mar 29, 2021
- Enrollment
- 1975
- Arms / groups
- 3 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Bharat Biotech International LimitedLead sponsor
- Georgia Institute for Clinical Research, LLCCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.